ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.91
+1.84%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$15.03
From 52W high−33.64%
Volume3.49M
Market cap$5.21B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$15.03
From 52W high
−33.64%
Volume
3.49M
Market cap
$5.21B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.6x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+1.84%
YTD Return
+284.30%
SummaryUpdated Jun 1, 2026
Erasca, Inc. (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California. The company went public in July 2021 and focuses on developing targeted cancer therapies for patients with RAS/MAPK pathway-driven cancers. As a clinical-stage company, Erasca has no approved products or revenue yet, but maintains a robust pipeline of investigational drugs targeting various cancer types including lung cancer, colorectal cancer, acute myeloid leukemia, and brain tumors.
Similar companies
Latest newsMore news →
Tango Therapeutics, Inc. and Erasca, Inc. announced that their Phase 1/2 study of vopimetostat combined with ERAS-0015 is open for enrollment in patients with specified MTAP-deleted cancers.12h agoErasca, Inc. announced that Chief Operating Officer Nicholas (Nik) Chetwyn will depart effective November 2, 2026.20d ago